Having limped through a tough first half, four-legged former farmers’ co-operative NWF proposes to amputate a limb, its garden centres business, in order to reduce its high debt levels.
The north west-based group intends now to focus on its remaining distribution, fuels and animal feeds businesses. Excluding garden centres, which are now regarded as a ‘discontinued operation’, these remaining three drove sales forward 20.8% to £361.2m in the year to May but saw profits fall 27.6% to £4.2m due to the weak first half and significant investment in warehouse expansion.
Given that the economic outlook remains ‘uncertain’ due to the unpredictability of feed commodity prices and demand for fuels, NWF has become ever more concerned with its net debt levels, which stood at £52.1m at year end. The company has negotiated medium-term banking facilities ‘with significant headroom’ and house broker Charles Stanley expects the group will receive around £10m from the garden centres sale.
Chief executive Richard Whiting remains sanguine despite the uncertainties clouding the horizon, buoyed by the strong second half recovery. The distribution business is now at full capacity and 'has the potential to make over £2m-plus' of profit now, with management able to now negotiate with a stronger hand for higher margin business.
The fuels and feeds divisions have both been victims of turbulent raw materials prices, but with there being a shortage of milk produced in the UK, farmers will continue to expand their herds and their demand for feed. The fuels operation, says Whiting, profited despite the volatility of supply and demand and has now proved it can do so.
Charles Stanley has revised its current year forecasts, excluding garden centres, to profits of £4.7m, earnings of 6.7p per share and a dividend of 4.1p. Down by more than half since January the shares offer recovery potential but not for the risk averse. Hold.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Market cap: £40.33m
PE Forecast: 12.8
Share price: 86p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.